Taysha Gene Therapies, Inc. Increase (Decrease) in Due to Related Parties
Taysha Gene Therapies, Inc. (TSHA) reported Increase (Decrease) in Due to Related Parties of -$8.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedParties · last filed 2023-03-28
- Taysha Gene Therapies, Inc. increase (decrease) in due to related parties for the quarter ending 2021-12-31 was $0.00.
- Taysha Gene Therapies, Inc. increase (decrease) in due to related parties for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Taysha Gene Therapies, Inc. increase (decrease) in due to related parties for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Taysha Gene Therapies, Inc. increase (decrease) in due to related parties for the quarter ending 2021-03-31 was -$8.00K, a 260.00% decline year-over-year.
- Taysha Gene Therapies, Inc. increase (decrease) in due to related parties for fiscal 2021 was -$8.00K, a 900.00% decline from fiscal 2020.
- Taysha Gene Therapies, Inc. increase (decrease) in due to related parties for fiscal 2020 was $1.00K.
| Period end | Increase (Decrease) in Due to Related Parties 0 month | Increase (Decrease) in Due to Related Parties 3 month | Increase (Decrease) in Due to Related Parties 6 month | Increase (Decrease) in Due to Related Parties 9 month | Increase (Decrease) in Due to Related Parties 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 derived: sum of 3 quarters · filed 2023-03-28 | -$8.00K 10-K · filed 2023-03-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | -$8.00K 10-Q · filed 2022-11-08 | -$67.00K derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$8.00K 10-Q · filed 2022-08-11 | -$67.00K derived: sum of 3 quarters · filed 2022-08-11 | -$21.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$8.00K 10-Q · filed 2022-05-16 | -$67.00K derived: sum of 2 quarters · filed 2022-05-16 | -$21.00K derived: sum of 3 quarters · filed 2022-05-16 | -$12.00K derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$13.00K derived: sum of 2 quarters · filed 2022-03-31 | -$4.00K derived: sum of 3 quarters · filed 2022-03-31 | $1.00K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $55.00K derived: sum of 2 quarters · filed 2021-11-10 | $60.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $14.00K 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | $5.00K 10-Q · filed 2021-05-11 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |